The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus after its global partner, Acadia Pharmaceuticals, secured European approval for DAYBU (trofinetide) – the first treatment for Rett syndrome in the EU. Neuren stands to receive US$35 million upon the drug’s first commercial sale in Europe, plus potential milestone payments.

What did Neuren report?

• The European Commission has granted marketing authorisation for DAYBU (trofinetide) for Rett syndrome.
• DAYBU is the first and only approved treatment for Rett syndrome in the European Union.
• Neuren to receive US$35 million from the first European commercial sale, with milestone payments up to US$170 million.
• Tiered royalties from mid-teens to low 20s percent of net sales are also expected under the partnership.
• Commercial launch in Germany is targeted for early Q4 2026.

What else do investors need to know?

The European approval means DAYBU can be marketed across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. This milestone further extends the reach of trofinetide, which is already approved in the United States, Canada, and Israel.

Neuren’s other clinical program, NNZ-2591, is progressing with a Phase 3 clinical trial for Phelan-McDermid syndrome and open-label extension studies. Each of Neuren’s drug development programs has been granted “orphan drug” status in both the US and EU.

What did Neuren management say?

Neuren CEO Jon Pilcher said:

We are delighted for the Rett syndrome community in Europe, who, until now, have had no approved treatment for this devastating condition. The European Commission’s approval of DAYBU is particularly rewarding for Neuren given our long-standing commitment to developing therapies for serious neurological disorders with profound unmet need. We look forward to seeing our partner Acadia make DAYBU available for Rett patients and families in Europe.

What’s next for Neuren?

With European marketing authorisation, Acadia plans to launch DAYBU in Germany in early Q4 2026, which will trigger Neuren’s first commercial milestone payment. Ongoing development of NNZ-2591, now in late-stage trials for several neurodevelopmental disorders, remains a key priority for future growth.

Neuren continues to target serious neurological conditions where few approved treatments exist, aiming to advance both its existing partnerships and its internal drug pipeline.

Neuren share price snapshot

The Neuren Pharmaceuticals share price has outperformed the S&P/ASX 200 index (ASX: XJO) over the past 12 months with a gain of approximately 27%.

View Original Announcement

The post Neuren share price in focus after DAYBU wins EU approval for Rett syndrome appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• 3 ASX 200 stocks storming higher this week on big news
• 5 ASX 200 broker buy ratings
• Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The ASX dividend share MFF Capital Investments Ltd (ASX: MFF) is one of the leading choices for passive income, in my view.

It may not be as popular as names like BHP Group Ltd (ASX: BHP), Commonwealth Bank of Australia (ASX: CBA) or Woolworths Group Ltd (ASX: WOW). But, I think MFF is better than each of those ASX blue-chip shares for multiple reasons.

Let’s get into what makes it such a good buy.

Diversification

Each of the large ASX companies I mentioned above is an impressive business with significant operations.

However, an investment with MFF offers much more diversification because it owns a portfolio of shares, whereas the ASX blue-chips are singular businesses.

MFF aims to invest in competitively advantaged businesses, which are normally global blue-chip stocks.

Its largest holdings are names like Mastercard, Alphabet, Visa, Bank of America and Amazon.

The ASX dividend share’s holdings have been long-term winners, and I believe there’s a good chance they will continue to be long-term compounders.

Past performance is not a guarantee of future performance, but MFF’s portfolio has delivered strong returns over the long-term.

According to CMC Invest, over the past five years MFF has delivered an average total shareholder return (TSR) of 16.2% per year.

I think its investment strategy can continue to perform well over the long-term and I expect its portfolio will continue to adjust over the years.

Dividend yield

One of the best reasons to like this ASX dividend share is down to its impressive dividend yield, which is superior to the ASX blue chip shares of CBA, BHP and Woolworths.

The business has provided guidance that it intends its next half-year dividend will be 12 cents per share and I expect the one after that will be 13 cents per share.

Assuming the business does pay an annual dividend per share of 25 cents per share in the 2027 financial year, it would represent a grossed-up dividend yield of 6.8%, including franking credits, at the time of writing.

Payout growth

Dividend growth is not a guarantee of course, but the business has a goal of increasing its dividend for investors each year and its large profit reserve and profit generation mean the business is able to pay consistently growing dividends.

In FY26 it grew its annual dividend per share by 23.5%, and I expect it will grow the dividend by another 19%. In my view, there are not many ASX dividend shares with yields above 6% that are likely to grow their payout at that pace.

MFF has grown its annual dividend per share each year since FY18, so it’s building a pleasing track record of regular payout growth.

This ASX dividend share is one of the largest positions in my portfolio, and I’m expecting more pleasing payouts in the years to come.

The post Why I’d buy this top ASX dividend share for major passive income today appeared first on The Motley Fool Australia.

More reading

• How much is needed in superannuation to target a $40,000 annual passive income?
• I’d buy 36,519 shares of this ASX stock to aim for $1,000 a month of passive income
• How much is needed in superannuation to target a $2,000 monthly passive income?
• How much is needed in superannuation to target a $90,000 annual passive income?
• This ASX dividend stock is growing its payouts like clockwork

Bank of America is an advertising partner of Motley Fool Money. Motley Fool contributor Tristan Harrison has positions in Mff Capital Investments. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet, Amazon, Mastercard, and Visa. The Motley Fool Australia has positions in and has recommended Mff Capital Investments. The Motley Fool Australia has recommended Alphabet, Amazon, Mastercard, and Visa. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Nanosonics Ltd (ASX: NAN) share price is in focus today after the company posted FY26 revenue of $203.9 million, up 3% on the prior year, and reported strong growth in trophon unit placements and successful launches of next-generation devices.

What did Nanosonics report?

• Revenue increased 3% on prior corresponding period (pcp) to $203.9 million, or 6% on a constant currency basis to $211.5 million
• EBIT came in at $16.0 million, down 10% on pcp, but up 21% to $21.6 million at constant currency
• trophon-only EBIT was $50.6 million, a 5% increase on pcp (16% at constant currency)
• Total trophon unit placements rose 9% to 4,230 units, with global installed base up 6% to 39,230 devices
• Cash and cash equivalents stood at $155.2 million as at 30 June 2026, and the company remains debt free
• $20 million share buyback completed, with a new buyback of up to $40 million announced for FY27

What else do investors need to know?

Nanosonics launched its next generation trophon3 and trophon2 Plus systems during FY26, seeing accelerating adoption in the second half of the year. North America was a key driver, with record device upgrades up 32% on last year.

The company continued making headway with the CORIS System, progressing through a Controlled Market Release and receiving favourable customer feedback. Regulatory milestones were achieved, including approvals in major markets and FDA clearances.

What did Nanosonics management say?

CEO and President said Michael Kavanagh said:

Nanosonics is entering a defining period of growth. FY26 demonstrated the strength of the business we have built: a proven trophon franchise, disciplined financial execution and in FY27 we will progress the CORIS System from CMR to commercialisation.

What’s next for Nanosonics?

Looking ahead, Nanosonics expects continued revenue growth driven by its expanding trophon installed base, upgrades, and consumables and services. The commercial launch of CORIS is planned across the UK, Ireland and Australia in the first half of FY27, with the US to follow.

The company has flagged a deliberate increase in operational expenses to support the CORIS commercialisation, but remains well-funded to pursue long-term opportunities. FY27 revenue guidance is between $220 million and $228 million (constant currency) with gross margin expected to moderate as new investments ramp up.

Nanosonics share price snapshot

Over the past 12 months, Nanosonics shares have declined 10%, trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement

The post Nanosonics posts FY26 revenue growth and prepares to launch CORIS appeared first on The Motley Fool Australia.

More reading

• Tyro Payments FY26: Earnings rise, growth outlook improves
• ARB Corporation shares: FY26 profit drops but growth investments strengthen outlook
• Southern Cross Gold reports drilling results
• Viva Energy Group posts record 1H26 earnings, boosts dividend
• Mader Group FY26 earnings: Profit jumps 15% on record revenue

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics. The Motley Fool Australia has recommended Nanosonics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.